CureVac N.V.
3.93
-0.01 (-0.25%)
At close: Jan 14, 2025, 3:59 PM
3.95
0.51%
Pre-market Jan 15, 2025, 04:03 AM EST
undefined%
Bid 3.95
Market Cap 881.52M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) 0.48
PE Ratio (ttm) 8.19
Forward PE n/a
Analyst Hold
Ask 4
Volume 941,328
Avg. Volume (20D) 720,404
Open 3.97
Previous Close 3.94
Day's Range 3.92 - 4.20
52-Week Range 2.21 - 5.28
Beta undefined

About CVAC

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 cli...

Industry Biotechnology
Sector Healthcare
IPO Date Aug 14, 2020
Employees 999
Stock Exchange NASDAQ
Ticker Symbol CVAC

Analyst Forecast

According to 3 analyst ratings, the average rating for CVAC stock is "Hold." The 12-month stock price forecast is $10, which is an increase of 154.45% from the latest price.

Buy 33.33%
Hold 66.67%
Sell 0.00%
Stock Forecasts

Next Earnings Release

CureVac N.V. is scheduled to release its earnings on Apr 23, 2025, before market opens.
Analysts project revenue of $6.50M, reflecting a -73.51% YoY shrinking and earnings per share of -0.12, making a -70.73% decrease YoY.
1 week ago · Source
+5.41%
Shares of vaccine makers are trading higher after ... Unlock content with Pro Subscription
1 week ago · Source
+5.41%
Shares of vaccine makers are trading higher after the first bird flu death was reporting in the US. Additionally, a recent DCD report noted an increase in acute respiratory illness activity.